

GCTK

biotech

medical devices

FDA

diabetes

momentum

dilution risk

clinical trials

GCTK: Pre-Market Surge Follows Journal Publication as FDA Filing Approaches

May 6, 2026 — 9:02 AM EDT · Report #62 · Free Equity Reports Research

SUMMARY

GlucoTrack surges 37% pre-market as peer-reviewed diabetes monitor study publication builds momentum ahead of critical FDA filing expected within 4-8 weeks.

SINCE REPORT -59.9%

DATA BOX

Price	\$1.00
Change	+36.99%
Volume	638.7K
Float	~3.66M
Mkt cap	\$1.42M

Pre-market Session (9:01 AM ET) - May 6, 2026

Key Data:

- Price: \$1.00

- Previous Close: \$0.73
- Change: +36.99% (\$0.27)
- Volume (Friday): 638.7K
- Float: ~3.66M shares
- Market Cap: \$1.42M

GCTK gapped higher this morning after pre-market trading reached \$1.07, reflecting a +47.44% move since Friday's close. This follows last week's publication of peer-reviewed research in The Journal of Diabetes Research, adding scientific credibility to the company's implantable glucose monitor just weeks before a critical FDA submission.

Here's what happened: GlucoTrack announced the publication of a peer reviewed scientific article in The Journal of Diabetes Research on the long-term accuracy and stability of the Company's fully implantable continuous blood glucose monitoring (CBGM) system in an in-vivo ovine model, evaluated over periods of up to 240 days. The timing couldn't be better - this data package directly supports the company's planned Q2 IDE filing with the FDA.

The mechanics behind this move aren't just about one study. GCTK has been systematically building toward its FDA moment. The first-in-human study demonstrated excellent accuracy with a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs, a 99% data capture rate, and no procedure or device-related serious adverse events. Combined with three critical patents awarded in October and November 2025 relating to the Company's CBGM platform, including proprietary sensor chemistry, intravascular lead design, and low-power electronics, the scientific foundation is getting solid.

What separates GCTK's approach? Glucotrack's Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. That's a different game than current wearable monitors - measuring glucose directly from blood rather than interstitial fluid eliminates lag time issues that plague existing devices.

But let's address the elephant in the room: dilution risk. The arrangement gives Glucotrack optional access to up to \$20.0 million subject to market-price formulas; the prospectus registers 20,060,000 shares for resale, representing ~84% of outstanding shares as of April 27, 2026. That's a massive overhang. Additionally, Glucotrack filed a resale prospectus for 3,224,803 warrant shares, about 354% of its 910,688 shares outstanding earlier this year. The company has been diluting aggressively to fund operations.

The near-term catalyst calendar is clear: the Company plans to file requisite documents with the FDA during Q2 of 2026, with the study expected to initiate in the second half of 2026, subject to FDA approval of its IDE submission. That puts the IDE filing roughly 4-8 weeks away.

From a trading perspective, during the trading session on 2026-05-06, GlucoTrack shares reached a daily high of \$1.12 and a low of \$0.97, showing the kind of volatility you'd expect from a \$1.42M market cap biotech with major catalyst risk. The company's market capitalization stands at \$4.06M, with a daily trading volume of \$29.89M shares - that volume-to-market cap ratio screams momentum play.

The setup here depends on your risk tolerance. Bulls are betting the FDA filing goes smoothly and the trial enrollment happens on schedule. The science looks legitimate - peer-reviewed publications in respectable journals

don't happen by accident in medtech. But bears aren't wrong about the dilution monster lurking in the background. The company reported a net loss of \$19.4 million for the full year 2025 and utilized \$15.3 million in cash for operating and investing activities, with \$7.4 million in cash and equivalents as of December 31, 2025.

What to watch:

- Volume pattern through regular session - pre-market strength needs follow-through
- FDA IDE submission timing and market reaction
- Any additional dilution announcements before trial funding
- \$0.97 as immediate support; breakdown targets Friday's \$0.73 close
- Resistance likely around \$1.12 (today's pre-market high) and psychological \$1.50

For traders, this isn't a buy-and-hold diabetes play. This is a binary bet on FDA regulatory progress wrapped in a micro-cap shell with serious dilution overhang. Size accordingly.

This analysis is for informational purposes only and does not constitute investment advice.

This report is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making any investment decision.

